A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Launched by ELI LILLY AND COMPANY · Dec 1, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who are overtly healthy as determined by medical evaluation
• • Have a body mass index( BMI) within the range of 18.0 to 34.0 kg/m2, inclusive.
• • Are males or non-pregnant women of childbearing potential (WOCBP) or women not of childbearing potential (WNOCBP).
• Exclusion Criteria:
• • Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy
• • Have an abnormal blood pressure, pulse rate, or temperature as determined by the investigator
• • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing
• • Are lactating or pregnant

Trial Officials